Search Results for: 19

— Study to Evaluate SYN-004’s Ability to Prevent C. difficile Infection and Antibiotic-Associated Diarrhea — — Phase 2b Trial Expected to Enroll Approximately 370 Patients at up to 75 Global Clinical Sites — ROCKVILLE, Md., Sept. 28, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect […]

— Late-Breaker Oral Presentation at ICAAC/ICC 2015 Highlights Data from Novel Gut Microbiome Program — ROCKVILLE, Md., Sept. 21, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, presented data from its novel SYN-004 program that demonstrated SYN-004 protected the

ROCKVILLE, Md., Aug. 10, 2015 /PRNewswire/ — Achieved Planned Milestones for Company’s Lead Microbiome Drug Candidates Enhanced Senior Management Team to Maximize Strategic Opportunities Strengthens Balance Sheet to Support Microbiome Clinical Trials Conference Call Today, August 10, 2015, at 8:30 a.m. EDT Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to

Collaboration Targets Delivery of an Essential Enzyme via ActoBiotics™ Platform without Adverse Impact on Gut Microbiome GERMANTOWN, Md. and ROCKVILLE, Md., Aug. 10, 2015 /PRNewswire/ — Intrexon Corporation (NYSE:XON), a leader in synthetic biology, and Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases,

— Conference Call Scheduled for Monday, August 10, 2015 at 8:30 a.m. EDT — ROCKVILLE, Md., July 29, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and six months ended June

ROCKVILLE, Md., July 21, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced that it has closed the public offering of 15.3 million shares of common stock, including the fully exercised over-allotment option by the underwriters covering 2.0 million

ROCKVILLE, Md., July 16, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced that it has priced an underwritten public offering of 13.3 million shares of common stock at a price of $3.00 per share, for expected gross proceeds

ROCKVILLE, Md., July 15, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by

— Study to Evaluate Effect of SYN-010 in Reducing Methane Production in the Gut — — Methane Production is Perceived as the Underlying Cause of Pain, Bloating and Constipation Associated with IBS-C — ROCKVILLE, Md., June 29, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the

— Study to Evaluate SYN-004’s Antibiotic-Degrading Effect in the Gut in the Presence of Esomeprazole — ROCKVILLE, Md., June 12, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, dosed the first participant in a second Phase 2a clinical trial of